腹膜透析充分性中.ppt

Physiology of PeritonealDialysis, Adequacy and PET ( Peritoneal Equivalent Test);Anatomy of The Peritoneum;Anatomy of The Peritoneum;Transport Processes in PeritonealDialysis;Models of Peritoneal Transport;Transport Across the Peritoneal Endothelium:The Three Pore Model;Transport Across the Peritoneal Endothelium:The Three Pore Model (续);Water Transport in Aquaporin- 1Knockout Mice;;Ultrafiltration in PD:The Pore-Matrix Model;;;Effective Peritoneal Surface Area;Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd.;;;;;;;;Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd.;;;;;;;;;;;;;;;;;;;;残肾GFR 计算;Kt/V 计算;Ccr 的计算;;何谓“充分的”治疗;However, Hong Kong Data suggest…;ADEMEX: Treatment CharacteristicsEffects of Intervention;ADEMEX: Primary Outcome;Preservation of RRF provides a survival advantage in PD patients;K/DOQI 2006 Kt/V urea 1.7 for all types of PD No Creatinine Clearance Target Continuous Therapy (middle molecule clearance) ISPD 2006 Kt/V urea 1.7 for CAPD and APD Creatinine Clearance 45L/wk for APD Continuous Therapy (middle molecule clearance) China PD Practice Guidelines - 中华肾脏病杂志 2006;22(8):513 - 516 - KtV urea ≥ 1.5-1.7 Creatinine Clearance ≥40-50L/wk Continuous Therapy for anurics;Kt/V与CrCl的差异;Kt/V与CrCl的差异;Kt/V与CrCl的差异（续）;常用透析方式;经验处方;Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd.;决定腹膜清除率的重要因素;如何提高PD中的腹膜清除率 ;增加留腹液量;增加交换的次数;提高透析液张力;PD病人的小分子溶质清除情况;PD病人的小分子溶质清除情况 ;腹膜透析中钠的清除;留腹期间总钠清除（钠筛现象）;0;不同透析液中透析液/血浆(D/P)钠平衡曲线;处方调整需要考虑的几个方面;关于提高溶质转运的处方调整方案(in China);小 结;Have a Good day!